NZ733480A - Human antibodies to fel d1 and methods of use thereof - Google Patents
Human antibodies to fel d1 and methods of use thereofInfo
- Publication number
- NZ733480A NZ733480A NZ733480A NZ73348013A NZ733480A NZ 733480 A NZ733480 A NZ 733480A NZ 733480 A NZ733480 A NZ 733480A NZ 73348013 A NZ73348013 A NZ 73348013A NZ 733480 A NZ733480 A NZ 733480A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibodies
- fel
- allergen
- methods
- basophils
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642083P | 2012-05-03 | 2012-05-03 | |
| US201261718044P | 2012-10-24 | 2012-10-24 | |
| US201361783312P | 2013-03-14 | 2013-03-14 | |
| NZ701124A NZ701124A (en) | 2012-05-03 | 2013-05-02 | Human antibodies to fel d1 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ733480A true NZ733480A (en) | 2019-03-29 |
Family
ID=48326501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701124A NZ701124A (en) | 2012-05-03 | 2013-05-02 | Human antibodies to fel d1 and methods of use thereof |
| NZ733480A NZ733480A (en) | 2012-05-03 | 2013-05-02 | Human antibodies to fel d1 and methods of use thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701124A NZ701124A (en) | 2012-05-03 | 2013-05-02 | Human antibodies to fel d1 and methods of use thereof |
Country Status (33)
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| PT2564695E (pt) | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
| WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| WO2015027154A2 (en) * | 2013-08-23 | 2015-02-26 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| NL2013554B1 (en) | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| SMT202000438T1 (it) | 2014-11-17 | 2020-09-10 | Regeneron Pharma | Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20 |
| PL3277725T3 (pl) | 2015-03-30 | 2021-06-14 | Regeneron Pharmaceuticals, Inc. | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| US10835600B2 (en) * | 2015-09-08 | 2020-11-17 | Universität Zürich | Compositions against cat allergy |
| AU2017252527A1 (en) | 2016-04-18 | 2018-11-08 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| WO2018118713A1 (en) * | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| MX381157B (es) * | 2017-01-24 | 2025-03-12 | Nestle Sa | Composiciones que comprenden anticuerpos anti-fel d1 y métodos para reducir al menos un síntoma de la alergia humana a los gatos. |
| SG11201912548XA (en) | 2017-07-06 | 2020-01-30 | Regeneron Pharma | Cell culture process for making a glycoprotein |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| SG11202005235WA (en) | 2018-01-31 | 2020-07-29 | Regeneron Pharma | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202516175A (zh) | 2018-03-19 | 2025-04-16 | 美商再生元醫藥公司 | 微晶片毛細管電泳分析及試劑 |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| EP3794026A4 (en) * | 2018-05-18 | 2022-06-22 | Chan Zuckerberg Biohub, Inc. | METHODS FOR ISOLATION OF ALLERGEN-SPECIFIC ANTIBODIES FROM HUMANS AND THEIR USES |
| CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| CA3100038A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| MX2021008590A (es) | 2019-01-16 | 2021-08-11 | Regeneron Pharma | Metodos para caracterizar enlaces de disulfuro. |
| MX2021013519A (es) | 2019-05-13 | 2021-12-10 | Regeneron Pharma | Ensayos de union de ligandos competitivos mejorados. |
| KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP7682174B2 (ja) | 2019-11-25 | 2025-05-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 非水性エマルションを使用した持続放出製剤 |
| MY200781A (en) | 2020-01-21 | 2024-01-15 | Regeneron Pharma | Deglycosylation methods for electrophoresis of glycosylated proteins |
| EP4204449A1 (en) | 2020-08-26 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| CA3192999A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| IL303027A (en) | 2020-11-25 | 2023-07-01 | Regeneron Pharma | Sustained release formulations by creating a non-aqueous membrane emulsion |
| CA3205135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| CA3202197A1 (en) | 2021-01-20 | 2022-07-28 | Reginald Smith | Methods of improving protein titer in cell culture |
| US20220404369A1 (en) | 2021-03-03 | 2022-12-22 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| EP4305190A4 (en) | 2021-03-11 | 2025-03-26 | Iggenix, Inc. | METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION |
| WO2022204728A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| MX2024004108A (es) | 2021-10-07 | 2024-04-19 | Regeneron Pharma | Calibracion y correccion de medidor de ph. |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| IL312372A (en) | 2021-10-26 | 2024-06-01 | Regeneron Pharma | Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures |
| CN114113278B (zh) * | 2021-11-24 | 2024-08-02 | 中国计量科学研究院 | 一种基于质谱的体外诊断试剂抗体的表位定位方法 |
| US20230174632A1 (en) * | 2021-12-08 | 2023-06-08 | IgGenix, Inc. | Combinations for allergy therapy |
| US20230296559A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| EP4544081A1 (en) | 2022-06-23 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Methods of identifying and evaluating cat allergy gene signatures in a subject by determining a stratified score based on gene expression |
| EP4634659A1 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| IL322811A (en) | 2023-03-01 | 2025-10-01 | Regeneron Pharma | Anti-FEL D1 antibody formulations |
| WO2024200854A1 (en) | 2023-03-31 | 2024-10-03 | Alk-Abelló A/S | Allergen binding antibodies suitable for treating tree pollen allergies |
| WO2024229136A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| CN117004650B (zh) * | 2023-06-25 | 2024-05-14 | 山东立菲生物产业有限公司 | 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| TW202532098A (zh) | 2023-09-29 | 2025-08-16 | 美商再生元醫藥公司 | 使用控制成核之冷凍乾燥 |
| CN117069865B (zh) * | 2023-10-12 | 2024-03-01 | 中国农业科学院饲料研究所 | 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| CN117964767B (zh) * | 2024-03-29 | 2024-08-06 | 北京恩泽康泰生物科技有限公司 | 抗rage抗体、细胞外囊泡及其制备方法和应用 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512283A (en) | 1990-07-06 | 1996-04-30 | Allergene, Inc. | Methods for the selective suppression of an immune response to dust mite der Pi |
| AU3591793A (en) * | 1992-01-21 | 1993-08-03 | Immulogic Pharmaceutical Corporation | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| WO1994014475A1 (en) * | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| NZ561040A (en) * | 2005-03-18 | 2009-04-30 | Cytos Biotechnology Ag | Cat allergen fusion proteins and use thereof |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| GB0513878D0 (en) * | 2005-07-06 | 2005-08-10 | Mars Inc | Cat allergen |
| WO2007065633A1 (en) * | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007113633A2 (en) * | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP1921142A1 (en) * | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| CA2681974C (en) * | 2007-03-29 | 2019-12-31 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2666787B1 (en) * | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| DK2162133T3 (en) | 2007-07-09 | 2016-10-24 | Nestec Sa | Approaches to reduce allergies caused by environmental allergens |
| BRPI0815370B8 (pt) * | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CN106267189B (zh) | 2010-10-06 | 2021-02-26 | 瑞泽恩制药公司 | 含有抗白介素-4受体(il-4r)的抗体的稳定制剂 |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| WO2015027154A2 (en) | 2013-08-23 | 2015-02-26 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| WO2018118713A1 (en) | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
-
2013
- 2013-05-01 JO JOP/2013/0131A patent/JO3820B1/ar active
- 2013-05-02 SM SM20250396T patent/SMT202500396T1/it unknown
- 2013-05-02 DK DK13721544.8T patent/DK2844672T3/da active
- 2013-05-02 SM SM20200241T patent/SMT202000241T1/it unknown
- 2013-05-02 RS RS20200539A patent/RS60282B1/sr unknown
- 2013-05-02 RU RU2014148502A patent/RU2658491C2/ru active
- 2013-05-02 EP EP25194366.8A patent/EP4653056A2/en active Pending
- 2013-05-02 EP EP21194412.9A patent/EP3978522B1/en active Active
- 2013-05-02 SG SG11201406748QA patent/SG11201406748QA/en unknown
- 2013-05-02 FI FIEP21194412.9T patent/FI3978522T3/fi active
- 2013-05-02 CN CN201380035000.9A patent/CN104411719B/zh active Active
- 2013-05-02 LT LTEP21194412.9T patent/LT3978522T/lt unknown
- 2013-05-02 TW TW102115645A patent/TWI644921B/zh active
- 2013-05-02 TW TW106119738A patent/TW201803901A/zh unknown
- 2013-05-02 CN CN201910294004.8A patent/CN110240651B/zh active Active
- 2013-05-02 MY MYPI2020006733A patent/MY195564A/en unknown
- 2013-05-02 PT PT137215448T patent/PT2844672T/pt unknown
- 2013-05-02 PL PL19218187T patent/PL3660047T3/pl unknown
- 2013-05-02 MY MYPI2017701565A patent/MY181422A/en unknown
- 2013-05-02 HU HUE13721544A patent/HUE049440T2/hu unknown
- 2013-05-02 PT PT192181873T patent/PT3660047T/pt unknown
- 2013-05-02 NZ NZ701124A patent/NZ701124A/en unknown
- 2013-05-02 ES ES19218187T patent/ES2898372T3/es active Active
- 2013-05-02 HR HRP20211932TT patent/HRP20211932T1/hr unknown
- 2013-05-02 PL PL13721544T patent/PL2844672T3/pl unknown
- 2013-05-02 SI SI201332111T patent/SI3978522T1/sl unknown
- 2013-05-02 ES ES13721544T patent/ES2780392T3/es active Active
- 2013-05-02 BR BR112014026852-5A patent/BR112014026852B1/pt active IP Right Grant
- 2013-05-02 PT PT211944129T patent/PT3978522T/pt unknown
- 2013-05-02 SI SI201331698T patent/SI2844672T1/sl unknown
- 2013-05-02 AU AU2013256251A patent/AU2013256251C1/en active Active
- 2013-05-02 KR KR1020147033137A patent/KR102185516B1/ko active Active
- 2013-05-02 EP EP13721544.8A patent/EP2844672B1/en active Active
- 2013-05-02 JP JP2015510445A patent/JP6400569B2/ja active Active
- 2013-05-02 SM SM20220014T patent/SMT202200014T1/it unknown
- 2013-05-02 RS RS20211475A patent/RS62636B1/sr unknown
- 2013-05-02 HR HRP20200652TT patent/HRP20200652T1/hr unknown
- 2013-05-02 DK DK21194412.9T patent/DK3978522T3/da active
- 2013-05-02 US US13/875,401 patent/US9079948B2/en active Active
- 2013-05-02 MX MX2014013371A patent/MX377634B/es active IP Right Grant
- 2013-05-02 CA CA2871077A patent/CA2871077C/en active Active
- 2013-05-02 ES ES21194412T patent/ES3049982T3/es active Active
- 2013-05-02 SI SI201331935T patent/SI3660047T1/sl unknown
- 2013-05-02 LT LTEP19218187.3T patent/LT3660047T/lt unknown
- 2013-05-02 LT LTEP13721544.8T patent/LT2844672T/lt unknown
- 2013-05-02 IN IN8767DEN2014 patent/IN2014DN08767A/en unknown
- 2013-05-02 HU HUE19218187A patent/HUE057062T2/hu unknown
- 2013-05-02 SG SG10202102919XA patent/SG10202102919XA/en unknown
- 2013-05-02 MY MYPI2014002857A patent/MY164101A/en unknown
- 2013-05-02 SG SG10201608378UA patent/SG10201608378UA/en unknown
- 2013-05-02 AR ARP130101494 patent/AR090914A1/es unknown
- 2013-05-02 NZ NZ733480A patent/NZ733480A/en unknown
- 2013-05-02 EP EP19218187.3A patent/EP3660047B1/en active Active
- 2013-05-02 WO PCT/US2013/039192 patent/WO2013166236A1/en not_active Ceased
- 2013-05-02 BR BR122019023685-2A patent/BR122019023685B1/pt active IP Right Grant
- 2013-05-03 UY UY34782A patent/UY34782A/es active IP Right Grant
-
2014
- 2014-10-08 ZA ZA2014/07302A patent/ZA201407302B/en unknown
- 2014-10-19 IL IL235121A patent/IL235121B/en active IP Right Grant
- 2014-11-03 MX MX2020003864A patent/MX2020003864A/es unknown
-
2015
- 2015-06-05 US US14/732,578 patent/US9475869B2/en active Active
-
2016
- 2016-09-13 US US15/263,848 patent/US10047152B2/en active Active
-
2017
- 2017-01-26 US US15/416,176 patent/US10047153B2/en active Active
- 2017-06-14 JP JP2017116808A patent/JP6603269B2/ja active Active
-
2018
- 2018-05-03 AU AU2018203087A patent/AU2018203087B9/en active Active
- 2018-07-05 US US16/028,275 patent/US11174305B2/en active Active
-
2020
- 2020-05-04 CY CY20201100408T patent/CY1124023T1/el unknown
- 2020-08-25 ZA ZA2020/05273A patent/ZA202005273B/en unknown
-
2021
- 2021-10-13 US US17/500,418 patent/US12252530B2/en active Active
- 2021-12-20 CY CY20211101115T patent/CY1124819T1/el unknown
-
2022
- 2022-03-09 ZA ZA2022/02846A patent/ZA202202846B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202202846B (en) | Human antibodies to fel d1 and methods of use thereof | |
| PH12019550238A1 (en) | Human antibodies to bet v 1 and methods of use thereof | |
| IL285475A (en) | Anti-blood dendritic cell antigen 2 antibodies and uses thereof | |
| UA104663C2 (xx) | Антитіло, що зв'язує cd127$антитело, связывающее cd127 | |
| PH12013500564A1 (en) | Anti-cd48 antibodies and uses thereof | |
| UA111340C2 (uk) | Антитіло, яке специфічно зв'язується з tnf-альфа людини | |
| TW200801041A (en) | Antibodies against human IL-22 and uses therefor | |
| MY171180A (en) | Anti-hla-b*27 antibodies and uses thereof | |
| PH12014502527B1 (en) | St2 antigen binding proteins | |
| EA201590247A1 (ru) | Антитела к siglec-15 | |
| HK1207654A1 (en) | Modified antibody regions and uses thereof | |
| EP3453723A3 (en) | Anti-asic1 antibodies and uses thereof | |
| CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
| WO2014165524A3 (en) | Methods and compositions for treating and preventing disease associated with avb8 integrin | |
| AR117721A2 (es) | Anticuerpos humanos para fel d1 y métodos para usarlos | |
| EA201992651A1 (ru) | АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| HK1190415A (en) | Humanised anti-cd52 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2021 BY ANAQUA SERVICES Effective date: 20200424 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2022 BY ANAQUA SERVICES Effective date: 20210421 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2023 BY ANAQUA SERVICES Effective date: 20220423 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2024 BY ANAQUA SERVICES Effective date: 20230420 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2025 BY ANAQUA SERVICES Effective date: 20240418 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2026 BY ANAQUA SERVICES Effective date: 20250423 |